Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Kim (NPI 1972763530)

Field	Value
Entity Type	Individual
Organization	David Kim
Address	1000 Galloping Hill Rd
City	Union
State	NJ
ZIP	07083
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	June 16, 2008

Payer Source	Total Paid
Medicare	$3.4M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-only biller: Total Medicare revenue is $3.4M while there is no Medicaid billing on file, which means payer mix is heavily concentrated on Medicare and the practice should be evaluated primarily through its Medicare activity. The absence of Medicaid claims suggests limited exposure to state program reimbursement rules or member panels.

Revenue is highly concentrated in a small number of high-value codes: the precomputed top-3 Medicare codes account for 73.0% of total Medicare revenue, led by J0178 at 52.5% of Medicare revenue. That concentration indicates the practice’s financial performance is driven by a narrow set of services, creating sensitivity to utilization or pricing changes for those codes.

The service mix is characteristic of an interventional retinal practice: J0178 (injection, aflibercept) with 2.6K claims and $1.8M revenue, J2778 (ranibizumab) with 2.1K claims and $400.2K revenue, and frequent comprehensive ophthalmology visits under 92014 (2.8K claims, $289.4K revenue) point to a workflow centered on high-volume intravitreal anti-VEGF injections supported by office-based retinal exams. Additional imaging activity such as 92134 (2.8K claims, $100.2K revenue) reinforces that the practice combines injection therapy with frequent diagnostic follow-up.

Despite the large dollar share from J0178, the provider’s national standing for that injection is not exceptional: J0178 ranks #292 of 3204 providers nationally (91th percentile; typical, unremarkable volume for this code) and J2778 ranks #204 of 1208 (83th percentile; typical, unremarkable volume for this code). In other words, the practice is a significant revenue generator from anti-VEGF drugs locally but does not appear to be a dominant national outlier for those drug codes.

Conversely, the provider is an extreme outlier on professional evaluation and imaging codes, which signals unusually high visit and diagnostic volume: 92014 ranks #83 of 35415 providers (100th percentile; extreme outlier, far above typical national volume), 92134 ranks #496 of 26868 providers (98th percentile; extreme outlier, far above typical national volume), and 92202 ranks #52 of 2327 providers (98th percentile; extreme outlier, far above typical national volume). These standings suggest a very large established patient panel or unusually high follow-up intensity relative to peers.

Ancillary and less-common drug codes contribute modestly to revenue and appear typical in national standing: Q5128 generates $118.3K (3.5% of Medicare revenue) and ranks #216 of 373 providers (42th percentile; typical, unremarkable volume), while J3590 contributes $109.8K (3.3% of Medicare revenue) and ranks #417 of 631 (33th percentile; typical, unremarkable volume). This indicates some diversification beyond branded anti-VEGF agents but no marked specialty activity in rare biologics billing.

Operationally, the claim volumes and average paid amounts point to significant drug procurement and infusion/clinic throughput implications for payers and network managers: J0178 shows 2.6K claims at $687 avg paid/claim for $1.8M revenue, and J2778 shows 2.1K claims at $187 avg paid/claim for $400.2K revenue. For contracting and utilization management, these specific code-level volumes make this practice a notable focal point for anti-VEGF utilization reviews and drug spend strategies.

The provider has long tenure in Medicare enrollment, with an NPI enumerated date of 2008-06-16 (~18 years ago), which supports the view that these billing patterns reflect an established practice rather than a new entrant or short-term fluke. Longitudinal relationships with the Medicare population likely underlie the high 92014 and 92134 volumes observed.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

19 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	2,570	$690	$1.8M
J2778	Injection, ranibizumab, 0.1 mg	2,140	$190	$400.2K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	2,780	$100	$289.4K
J2777	Injection, faricimab‑svoa, 0.1 mg	8,820	$30	$255.8K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	2,070	$100	$208.7K
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	550	$220	$118.3K
J3590	Unclassified biologics	50	$2,150	$109.8K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	2,780	$40	$100.2K
J3490	Unclassified drugs	10	$1,770	$24.8K
92202	The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece…	1,760	$10	$22.9K

Showing 1–10 of 19

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

David Kim — 5 of 19 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

19 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	3	90	880	$690	$693.6K
J2777	29	60	8,820	$30	$319K
J2778	9	40	1,140	$180	$240.8K
J3590	13	20	50	$2,180	$156.6K
Q5128	9	20	650	$210	$139K
67028	11	100	810	$100	$91.1K
J7312	14	10	190	$160	$42.3K
92014	8	1,130	160	$100	$34.9K
J3490	113	120	70	$230	$30.2K
92012	650	800	140	$70	$18.5K

Showing 1–10 of 19

Related Providers

Other providers that share a Tax Identification Number (TIN) with David Kim, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Associated Retinal Consultants LLC	DE	Ophthalmology Physician	$0	$25.2M
Rohit Lakhanpal	MD	Retina Specialist (Ophthalmology) Physician	$6.1M	$0
Vinod Voleti	NJ	Retina Specialist (Ophthalmology) Physician	$4.1M	$0
Sumit Shah	NJ	Retina Specialist (Ophthalmology) Physician	$4.1M	$0
Newman Sund	MD	Ophthalmology Physician	$4M	$0
Eric Suan	MD	Ophthalmology Physician	$3.8M	$0
Matthew Speicher	MD	Ophthalmology Physician	$3.7M	$0
Howard Fine	NJ	Retina Specialist (Ophthalmology) Physician	$3.6M	$0
Timothy Polk	MD	Ophthalmology Physician	$3.5M	$0
Jonathan Prenner	NJ	Retina Specialist (Ophthalmology) Physician	$3.4M	$0

Nearby Providers

Other providers in the same ZIP code as David Kim, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lincoln Diagnostics LLC	NJ	Clinical Medical Laboratory	$3.2M	$24.3M
Lifestation, Inc.	NJ	Emergency Response System Companies	$0	$15.8M
Full Circle Health Services LLC	NJ	Home Health Agency	$0	$14M
Apollo Clinical Laboratories Inc.	NJ	Clinical Medical Laboratory	$825.9K	$12.4M
Gracious Home Care LLC.	NJ	Home Health Agency	$0	$12.2M
Bio-medical Applications Of New Jersey, Inc.	NJ	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$7.3M
New Jersey Interventional Associates LLC	NJ	Ambulatory Surgical Clinic/Center	$2.1M	$750.5K
Anjum Tanwir	NJ	Cardiovascular Disease Physician	$2.5M	$1.3K
Frank Tarantini	NJ	Vascular Surgery Physician	$1.9M	$2.3K
Leonard Feiner	NJ	Retina Specialist (Ophthalmology) Physician	$1.7M	$0

David Kim — Billing Profile & Reimbursement Data

Sign up for David Kim — Billing Profile & Reimbursement Data policy alerts

David Kim — Billing Profile & Reimbursement Data

Sign up for David Kim — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References